Minerva Neurosciences (NERV) investor relations material

Executive summary

• Initiated global confirmatory Phase 3 trial of roluperidone for negative symptoms in schizophrenia; first patient screened in March 2026, with topline results expected in the second half of 2027.

• No regulatory approvals or product revenue to date; company remains pre-commercial and continues to incur significant operating losses.

• Accumulated deficit reached $814.2 million as of March 31, 2026, with a net loss of $125.4 million for the quarter, up from $3.8 million in the prior year period.

• Presented open-label safety data showing no safety or drug-drug interaction concerns with roluperidone and olanzapine.

• Leadership transition announced: Jim O'Connor appointed Chief Business Officer and General Counsel, replacing Geoff Race, who remains as a consultant.

Financial highlights

• Research and development expenses rose to $5.3 million from $1.4 million year-over-year, mainly due to the initiation of the Phase 3 trial and higher compensation costs.

• General and administrative expenses increased to $11.4 million from $2.5 million, driven by a $6.6 million non-cash charge related to a settlement agreement and higher professional fees.

• Non-cash loss of $109.4 million recognized due to changes in fair value of warrant liability from the October 2025 private placement.

• Cash, cash equivalents, marketable securities, and restricted cash totaled $78.2 million at quarter-end.

• Net loss (GAAP) was $125.4 million ($2.86/share) for Q1 2026, compared to $3.8 million ($0.50/share) in Q1 2025; adjusted net loss (non-GAAP) was $7.3 million ($0.17/share).

Outlook and guidance

• Cash resources are expected to fund operating commitments for at least the next 12 months.

• Company anticipates continued operating losses and negative cash flows as it advances clinical development and prepares for potential commercialization.

• Additional capital will be required to complete development and commercialization of roluperidone and other candidates.

• Topline data from the 12-week Phase 3 trial expected in the second half of 2027.

• The trial aims to confirm efficacy on negative symptoms and assess relapse rates over an additional 40 weeks.